Symbicort SMART Satisfaction From Patient Perspective 2009
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Liam Chong Kin, Professor, Principal Investigator, Affiliation: UMMC
Overall contact:
AstraZeneca Malaysia Clinical Study Information, Phone: +603 20892288
Summary
To characterize the level of asthma control and patient satisfaction amongst diagnosed
asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy
(SMART) in Malaysia.
Clinical Details
Official title: Symbicort SMART Satisfaction From Patient Perspective 2009
Study design: Case-Only, Prospective
Primary outcome: Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ)Score level of Asthma Control Test (ACT)
Eligibility
Minimum age: 18 Years.
Maximum age: 59 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's
for the past 3 months
- Informed consent
Exclusion Criteria:
- Symbicort SMART treatment < 3 months
- Patients requiring short courses of oral steroids more than twice in a month
Locations and Contacts
AstraZeneca Malaysia Clinical Study Information, Phone: +603 20892288
Research Site, Petaling Jaya, Selangor, Malaysia; Recruiting
Additional Information
Starting date: August 2009
Ending date: December 2009
Last updated: September 9, 2009
|
